Kevin Charles Gorman, Chief Executive Officer at NEUROCRINE BIOSCIENCES INC (NBIX), sold 335,716 shares at $132.44 ($44.7M) on 2024-01-08, disclosed to the SEC on 2024-01-10.
Scheduled sale ($44.7M) by Chief Executive Officer under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $132.44 | 105,835 | $14.0M | 31.4% |
| 2 | $132.44 | 105,835 | $14.0M | 31.4% |
| 3 | $134.01 | 62,023 | $8.3M | 18.6% |
| 4 | $134.01 | 62,023 | $8.3M | 18.6% |
| Total | $133.02 avg | 335,716 | $44.7M | 100% |
| Filing → |
| NBIX | SELL | 2025-08-11 | $26.9M | — | Filing → |
| XNCR | SELL | 2025-06-16 | $29K | — | Filing → |
| NBIX | SELL | 2025-05-29 | $2.3M | — | Filing → |